Emcure Pharma delivers strong Q1 growth across domestic & international markets

New Delhi: Emcure Pharmaceuticals reported a strong start to the financial year, announcing its consolidated results for the quarter ended June 30, 2025, with significant growth across both domestic and international markets.

The company’s international business posted a 22 percent increase, driven by broad-based performance across geographies.

The rest of the world segment led the charge with a robust 42 percent growth, while the Canada business grew 16.4 percent, benefiting from new product launches and market share gains. In Europe, the early impact of new launches translated into a 12.8 percent increase.

The domestic business expanded by 9.4 percent, supported by solid performance in all key therapies and further boosted by initiatives in dermatology and the over-the-counter segment. During the quarter, Emcure deepened its strategic alliance with Sanofi, adding the Oral Anti-diabetic portfolio to its existing cardiovascular portfolio for marketing and distribution in India.

Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, expressed satisfaction with the company’s first-quarter results, emphasizing the consistent performance across all markets. He noted that the expanded partnership with Sanofi would strengthen Emcure’s position in the rapidly growing metabolic care segment. Mehta also highlighted the strength of the company’s product pipeline, both from in-house R&D and in-licensing agreements, as a driver for future growth. Operational efficiency, he added, would remain a key focus to ensure sustained margin improvements.

For the quarter, revenue from operations stood at Rs 2,101 crore, marking a year-on-year growth of 15.7 percent compared to Rs 1,815 crore in the same quarter last year. Domestic revenues reached Rs 995 crore, up 9.4 percent, while international revenues touched Rs 1,106 crore, a 22.1 percent increase. Within the international portfolio, emerging markets contributed Rs 360 crore, Europe generated Rs 403 crore, and Canada delivered Rs 342 crore.

Gross profit for the quarter came in at Rs 1,299 crore with a margin of 61.8 percent, compared to 62.4 percent in the prior year. Employee costs rose to Rs 393 crore, reflecting a 12.3 percent increase, while other expenses reached Rs 501 crore, up 12.5 percent year-on-year. EBITDA was Rs 404 crore, growing 20.1 percent over last year and representing a margin improvement to 19.23 percent from 18.53 percent.

Profit before tax stood at Rs 291 crore, up 40.2 percent, while profit after tax was Rs 215 crore, also showing a 40.8 percent year-on-year increase. PAT margins improved to 10.2 percent compared to 8.4 percent in the same period last year. The company’s financial performance underscores its ability to balance strong topline growth with operational efficiency, setting a positive tone for the rest of the financial year.